Untitled

doi:10.18632/oncotarget.v7i44

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found that PDL1 expression was associated with a prolonged OS in Extranodal Natural Killer/T-cell Lymphoma (ENKTCL) ( 17 ) and breast cancer ( 26 , 27 ). However, PDL1 expression was associated with shorter OS in pancreatic cancer, hepatocellular carcinoma and gastric cancer ( 26 , 28 ), and no association was observed between PDL1 expression and survival in patients with EOC ( 8 , 24 ). Our study showed an expression of PDL1 in 48.1% of HGSOC associated with an advanced stage and not correlated to 2-year OS in HGSOC.…”

Section: Discussionmentioning

confidence: 99%

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma

Jlassi,

Rejaibi,

Manai

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionImmunotherapy by blocking immune checkpoints programmed death/ligand (PD1/PDL1) and cytotoxic T-lymphocyte-associated protein 4(CTLA4) has emerged as new therapeutic targets in cancer. However, their efficacy has been limited due to resistance. A new- checkpoint V-domain Ig-containing suppressor of T cell activation (VISTA) has appeared, but the use of its inhibition effect in combination with antibodies targeting PDL1/PD1and CTLA4 has not been reported in ovarian cancer.MethodsIn this study, we investigated the expressions of VISTA, CTLA4, and PDL1 using immunohistochemistry (IHC)on 135 Formalin-Fixed Paraffin-Embedded (FFPE)tissue samples of High-grade serous carcinoma (HGSOC). VISTA, CTLA4, PDL1, PD1, CD8, CD4, and FOXP3 mRNA extracted from 429 patients with ovarian cancer in the Cancer Genome Atlas (TCGA) database was included as a validation cohort. Correlations between these checkpoints, tumor-infiltrating- lymphocytes (TILs), and survival were analyzed.Results and discussionCTLA4 was detectable in 87.3% of samples, VISTA in 64.7%, PD1 in 56.7%, and PDL1 in 48.1%. PDL1 was the only tested protein associated with an advanced stage (p=0.05). VISTA was associated with PDL1, PD1, and CTLA4 expressions (p=0.005, p=0.001, p=0.008, respectively), consistent with mRNA level analysis from the TCGA database. Univariate analyses showed only VISTA expression (p=0.04) correlated with overall survival (OS). Multivariate analyses showed that VISTA expression (p=0.01) and the coexpression of VISTA+/CTLA4+/PD1+ (p=0.05) were associated with better OS independently of the clinicopathological features. Kaplan-Meier analysis showed that the coexpression of the VISTA+/CTLA4+/PDL1+ and VISTA+/CTLA4+/PD1+ checkpoints on tumor cells (TCs)were associated with OS (p=0.02 and p<0.001; respectively). VISTA+/CTLA4+/PD1+ in TCs and CD4+/CD8+TILswere associated with better 2-yer OS. This correlation may refer to the role of VISTA as a receptor in the TCs and not in the immune cells. Thus, targeting combination therapy blocking VISTA, CTLA4, and PD1 could be a novel and attractive strategy for HGSOC treatment, considering the ambivalent role of VISTA in the HGSOC tumor cells.

show abstract

Section: Discussionmentioning

confidence: 99%

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma

Jlassi,

Rejaibi,

Manai

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…These biomarkers include neutrophils, monocytes, lymphocytes, hemoglobin (HGB), lactate dehydrogenase (LDH), and other hematological biomarkers. 6,7 However, few studies have conducted a comprehensive discussion of these hematological biomarkers. Hence, the value of these markers in determining the prognosis or the survival rate after CRC surgery should be further evaluated.…”

Section: Introductionmentioning

confidence: 99%

<p>Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics</p>

Long

Zang

Wang

et al. 2020

OTT

View full text Add to dashboard Cite

Background: There is a large difference in postoperative survival in patients with nonmetastatic colorectal cancer. We aimed to develop nomograms incorporating both hematological biomarkers and clinical characteristics to predict overall survival (OS) in patients with radical surgery for non-metastatic colorectal cancer. Methods: A retrospective analysis was performed on date from 508 patients who underwent radical resection of colorectal cancer at the Affiliated Tumor Hospital of Guangxi Medical University from December 2011 to December 2015. Simple random sampling was performed by dividing these patients into a training set (n=355) and validation set(n=153), which yielded a 7:3 ratio in the sample sizes between these groups. Based on COX regression analysis of the results from the training cohort, a nomogram was developed to predict the three-year and five-year overall survival rate, and internal verification was also performed. The nomogram prediction accuracy and discriminating ability were evaluated by Harrell's C-index (C-index), calibration curves and were compared with the colorectal cancer TNM staging system. Results: We found that age, degree of differentiation, T stage, N stage, neurological invasion, neutrophils, monocytes, HGB, and LDH were independent risk factors for predicting OS in patients with colorectal cancer. In the training cohort, the C index was 0.796 (95% CI: 0.761-0.831). In the validation cohort, the C index was 0.671 (95% CI: 0.656-0.686). The nomogram showed a stronger predictive ability than did TNM staging. Decision curve analysis showed that the nomogram had value in terms of clinical application. Conclusion: Our nomogram combined hematological biomarkers and clinical characteristics and was highly effective in predicting OS in patients with non-metastatic colorectal cancer. Hence, our nomogram may provide a reference tool for clinicians to guide individualized treatment and follow-ups for patients with colorectal cancer.

show abstract

Development and Assessment of a Model for Predicting Individualized Outcomes in Patients With Oropharyngeal Cancer

et al. 2021

View full text Add to dashboard Cite

Key Points Question Can a model be developed for individualized survival, locoregional recurrence, and distant metastasis prognostication for patients newly diagnosed with oropharyngeal cancer, incorporating clinical, oncologic, and imaging data? Findings In this prognostic study, model predictions for 5-year overall survival demonstrated excellent discrimination in cohort study training data for models with and without imaging variables. This model appeared to possess good calibration and well stratified patients in terms of likely outcomes among many competing events. Meaning This prognostic model and web-based application may serve as a useful tool to provide clinicians, researchers, and patients with oropharyngeal cancer robust, individualized prognostic estimations.

show abstract

Untitled

Abstract: ABSTRACT

Cited by 5 publications

References 21 publications

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma

<p>Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics</p>

Development and Assessment of a Model for Predicting Individualized Outcomes in Patients With Oropharyngeal Cancer

Contact Info

Product

Resources

About